SKion GmbH
https://www.skion.de/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SKion GmbH
Viking Plans To Go Directly To Phase III With Obesity Drug
In its Q2 earnings call, the biotech expressed optimism about developing VK2735 as a monthly injection, with an oral version moving into Phase II. An EOP2 meeting for its MASH drug is expected in Q4.
Slimmer, Faster: Roche Aims To Speed Its Obesity Pill To Market
Roche is taking a more hard-nosed approach to portfolio prioritization, and said in its Q2 call that it believes it can move faster with a more slimmed down R&D pipeline.
Roche Could Have The Best Obesity Pill
That is, if very early data in a handful of patients are borne out in later, larger studies.
Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry
Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?
Company Information
- Industry
- Miscellaneous
- Other Names / Subsidiaries
-
- Altana AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice